Prosecution Insights
Last updated: November 20, 2026
Application No. 18/265,421

TREATMENT OF DANON DISEASE

Final Rejection §102
Filed
Jun 05, 2023
Priority
Dec 07, 2020 — provisional 63/122,249 +2 more
Examiner
MONTANARI, DAVID A
Art Unit
1632
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Spacecraft Seven LLC
OA Round
2 (Final)
65%
Grant Probability
Moderate
3-4
OA Rounds
4m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 65% of resolved cases
65%
Career Allowance Rate
503 granted / 778 resolved
+4.7% vs TC avg
Strong +49% interview lift
Without
With
+49.4%
Interview Lift
resolved cases with interview
Typical timeline
3y 10m
Avg Prosecution
58 currently pending
Career history
842
Total Applications
across all art units

Statute-Specific Performance

§101
4.8%
-35.2% vs TC avg
§103
36.7%
-3.3% vs TC avg
§102
13.5%
-26.5% vs TC avg
§112
33.5%
-6.5% vs TC avg
Black line = Tech Center average estimate • Based on career data from 778 resolved cases

Office Action

§102
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Applicants arguments and amendments filed on 6/25/2026 have been entered. Claims 38, 49, 52 and 53 have been amended. In view of Applicants amendments the 112(b) rejection is withdrawn. In view of Applicants amendments the 102 rejection has been amended. Claims 38, 47, 49, 52, 53 and 57 are examined in the instant application. Claim Rejections - 35 USC § 102 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claim(s) 38, 47, 49, 52, 53 and 57 remain rejected under 35 U.S.C. 102(a)(1) as being anticipated by Keravala et al. (WO 2020/014523, published 1/16/2020) for reasons of record in the Non-Final Office Action mailed on 4/1/2026 (and repeated as amended below). Regarding claims 38 and 49, Keravala et al. teach pharmaceutical composition for treating Danon disease comprising an AAV comprising CAG promoter and a nucleotide sequence encoding a LAMP2B protein, wherein the therapeutic amount about 1 x 1013 vg/kg to about 6.7 x 1013 vg/kg (see Abstract, Fig. 1A, reproduced below, pg. 1 lines 26-28, pg. 32 line 7 bridge pg. 33 line 2 and pg. 35 lines 5-16). PNG media_image1.png 276 783 media_image1.png Greyscale Regarding claim 47 and SEQ ID NO: 1, Keravala teaches that their encoded LAMP2B protein (SEQ ID NO: 2) is 100% identical to instantly recited SEQ ID NO: 1. PNG media_image2.png 57 565 media_image2.png Greyscale Regarding claim 52, Keravala teaches: SEQ ID NO: 22 which is 100% identical instantly recited SEQ ID NO: 22 PNG media_image3.png 49 562 media_image3.png Greyscale SEQ ID NO: 3 which is 100% identical to instantly recited SEQ ID NO: 3 PNG media_image4.png 58 562 media_image4.png Greyscale SEQ ID NO: 75 which is 100% identical to instantly recited SEQ ID NO: 27 PNG media_image5.png 51 566 media_image5.png Greyscale SEQ ID NO: 42 which is 100% identical to instantly recited SEQ ID NO: 7 PNG media_image6.png 52 564 media_image6.png Greyscale Regarding claim 53, Keravala teaches: SEQ ID NO: 11 which is 100% identical to instantly recited SEQ ID NO: 11 PNG media_image7.png 60 567 media_image7.png Greyscale SEQ ID NO: 12, which is 100% identical to instantly recited SEQ ID NO: 12 PNG media_image8.png 58 569 media_image8.png Greyscale Regarding claim 57, with respect to the term kit, the claimed kit is not accorded any patentable weight, as it is directed to a composition comprising the pharmaceutical composition of the invention. Regarding instructions, the inclusion of instructions is not considered to provide a patentable limitation on the claims because the instructions merely represent a statement of intended use in the form of instructions in a kit. See In re Ngai, 367 F.3d 1336, 70 U.S.P.Q.2d 1862 (Fed. Cir. 2004) (holding that an inventor could not patent known kits by simply attaching new set of instructions to that product). Thus, the teachings of Keravala clearly anticipate the invention of claims 38, 47, 49, 52, 53 and 57. Response to Arguments Applicants argue that Keravala does not teach the therapeutic dose range in amended claim 38. This argument is not found persuasive as Kervala teaches the amended dose range as set forth above. Thus for the reasons above and of record the rejection is maintained. Conclusion No claims are allowed. THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to DAVID A MONTANARI whose telephone number is (571)272-3108. The examiner can normally be reached M-Tr 8-6. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Peter Paras can be reached at 571-272-4517. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. DAVID A. MONTANARI Examiner Art Unit 1632 /ANOOP K SINGH/Primary Examiner, Art Unit 1632
Read full office action

Prosecution Timeline

Jun 05, 2023
Application Filed
Apr 01, 2026
Non-Final Rejection mailed — §102
Jun 25, 2026
Response Filed
Sep 23, 2026
Final Rejection mailed — §102 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12799458
LIVER ORGANOID COMPOSITIONS AND METHODS OF MAKING AND USING SAME
7y 0m to grant Granted Nov 17, 2026
Patent 12747453
GENE-THERAPY VECTORS FOR TREATING CARDIOMYOPATHY
3y 1m to grant Granted Sep 29, 2026
Patent 12742181
GENE-THERAPY VECTORS FOR TREATING CARDIOMYOPATHY
3y 8m to grant Granted Sep 22, 2026
Patent 12703854
IN VITRO METHOD OF DIFFERENTIATING A HUMAN PLURIPOTENT STEM CELL POPULATION INTO A CARDIOMYOCYTE CELL POPULATION
4y 11m to grant Granted Aug 11, 2026
Patent 12698310
COMPOSITIONS AND METHODS FOR INSECT CONTROL
5y 0m to grant Granted Aug 04, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
65%
Grant Probability
99%
With Interview (+49.4%)
3y 10m (~4m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 778 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month